© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Biosimilars
MHE’s Most-Read Oncology News in 2020
December 29, 2020
Drug and diagnostic approvals and biosimilars news were popular with readers.
Talking Biosimilars With OneOncology’s Dr. Jeff Patton
October 31, 2020
The leading community oncology practice partnership has been an early adopter of biosimilars, and a trouble-shooter for hurdles with payers.
To Beat High Costs, California Moves to Create Its Own Drug Label
September 30, 2020
Health Plan Group Puts Biosimilars On Its Roadmap of Needed Healthcare Reforms
September 28, 2020
The Alliance of Community Health Plans calls for changes to get more biosimilars approved and on the market.
Proliferation of Biosimilars Could Be Costly for Oncologists, Warns Texas Oncology Policy Leader
September 28, 2020
Texas Oncology Executive Vice President Debra Patt says it will be unrealistically expensive for oncologists to keep many biosimilars for the same innovator product in their inventories.
The Benefits of Anti-TNF Biosimilars
August 18, 2020
Authors of a review say biosimilars would improve treatment, not just reduce cost.
Oncology Care Model Spurs Use of Biosimilar Filgrastim
August 17, 2020
Whether the OCM has worked out is debatable, but it has apparently encouraged the use of biosimilar versions of filgrastim.
When Will Biosimilars Start Making a Serious Difference in Oncology?
August 05, 2020
It's early days yet because patent and other issues have kept FDA-approved biosimilars off the market, but Gary Lyman, M.D., M.P.H.. of the Fred Hutchinson Cancer Research Center says there's evidence of some effect on the price of cancer supportive drugs.
Is the Biosimilars Waiting Game Finally Over?
July 30, 2020
Advocates say a number of regulatory changes could help bring more of these products on to the market.
Sandoz, Boehringer Ingelheim Battle Biosimilar Misinformation
July 24, 2020
Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.
Biosimilars for Cancer an 'Emerging Success' Says NCCN's Koh
July 09, 2020
Vote in May made FDA-approved biosimilars an "appropriate substitution" for brand-name biologics in NCCN guidelines.
FDA Approves Hulio, the Sixth Biosimilar to Humira
July 08, 2020
Along with the other Humira biosimilars, Hulio will not be on the market till 2023.
Biosimilars Fan Club Includes Free-Market Conservatives
July 06, 2020
Pacific Research Institute’s Winegarden Sees Dose of Competition as Way to Lower OOP Costs
Survey: Rheumatologists Still Reluctant to Switch Patients to Biosimilars
July 02, 2020
Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars.
Challenges of Developing the Next Generation of Biosimilars
June 04, 2020
Proving therapeutic equivalence is a major hurdle.
Understanding Biosimilar Development and Approvals
June 04, 2020
Developing a biosimilar can be more challenging than developing the innovator product because of the need to match the attributes of a highly complex molecules.
11 Trends Influencing Biosimilars in 2020
May 18, 2020
The purpose of biosimilar is simple: reduce healthcare costs, pure and simple. Here are 11 trends affecting biosimilars over the last year in the U.S.
Health Execs: Here are 5 Important Takeaways About the Current Situation With Biosimilars
May 18, 2020
Just as we’ve seen the entire healthcare landscape change in 2020 because of COVID-19, the world of biosimilars is ever-changing.
Biosimilars in the Pipeline
January 03, 2020
Several biosimilars will come to market within the next few years.